iSpecimen Statistics
Total Valuation
iSpecimen has a market cap or net worth of $4.13 million. The enterprise value is -$42,973.
| Market Cap | 4.13M |
| Enterprise Value | -42,973 |
Important Dates
The last earnings date was Friday, August 14, 2026, before market open.
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
iSpecimen has 2.52 million shares outstanding. The number of shares has increased by 1,153.73% in one year.
| Current Share Class | 2.52M |
| Shares Outstanding | 2.52M |
| Shares Change (YoY) | +1,153.73% |
| Shares Change (QoQ) | +308.49% |
| Owned by Insiders (%) | 0.00% |
| Owned by Institutions (%) | 2.31% |
| Float | 2.52M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 8.86 |
| Forward PS | n/a |
| PB Ratio | 1.44 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.82, with a Debt / Equity ratio of 0.14.
| Current Ratio | 0.82 |
| Quick Ratio | 0.81 |
| Debt / Equity | 0.14 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -30,883.58 |
Financial Efficiency
Return on equity (ROE) is -968.47% and return on invested capital (ROIC) is -407.82%.
| Return on Equity (ROE) | -968.47% |
| Return on Assets (ROA) | -87.69% |
| Return on Invested Capital (ROIC) | -407.82% |
| Return on Capital Employed (ROCE) | -491.60% |
| Weighted Average Cost of Capital (WACC) | 12.52% |
| Revenue Per Employee | $66,615 |
| Profits Per Employee | -$1.63M |
| Employee Count | 7 |
| Asset Turnover | 0.07 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -95.02% in the last 52 weeks. The beta is 1.63, so iSpecimen's price volatility has been higher than the market average.
| Beta (5Y) | 1.63 |
| 52-Week Price Change | -95.02% |
| 50-Day Moving Average | 2.26 |
| 200-Day Moving Average | 8.59 |
| Relative Strength Index (RSI) | 34.70 |
| Average Volume (20 Days) | 542,784 |
Short Selling Information
The latest short interest is 181,533, so 7.21% of the outstanding shares have been sold short.
| Short Interest | 181,533 |
| Short Previous Month | 184,505 |
| Short % of Shares Out | 7.21% |
| Short % of Float | 7.21% |
| Short Ratio (days to cover) | 1.52 |
Income Statement
In the last 12 months, iSpecimen had revenue of $466,302 and -$11.42 million in losses. Loss per share was -$21.95.
| Revenue | 466,302 |
| Gross Profit | -504,830 |
| Operating Income | -9.42M |
| Pretax Income | -11.42M |
| Net Income | -11.42M |
| EBITDA | -9.28M |
| EBIT | -9.42M |
| Loss Per Share | -$21.95 |
Balance Sheet
The company has $4.41 million in cash and $240,903 in debt, with a net cash position of $4.17 million or $1.66 per share.
| Cash & Cash Equivalents | 4.41M |
| Total Debt | 240,903 |
| Net Cash | 4.17M |
| Net Cash Per Share | $1.66 |
| Equity (Book Value) | 1.74M |
| Book Value Per Share | 1.14 |
| Working Capital | -992,538 |
Cash Flow
| Operating Cash Flow | -7.00M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 134,556 |
| Net Borrowing | n/a |
| Free Cash Flow | -7.00M |
| FCF Per Share | -$2.78 |
Margins
| Gross Margin | -108.26% |
| Operating Margin | -2,020.04% |
| Pretax Margin | -2,449.04% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
iSpecimen does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1,153.73% |
| Shareholder Yield | -1,153.73% |
| Earnings Yield | -276.48% |
| FCF Yield | -169.57% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | 118.33% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 28, 2026. It was a reverse split with a ratio of 1:40.
| Last Split Date | Apr 28, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:40 |
Scores
iSpecimen has an Altman Z-Score of -20.11 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -20.11 |
| Piotroski F-Score | 2 |